IPCALAB
IPCA Laboratories
Each stock's 10,000-path forecast, rendered as light.
IPCA Laboratories (IPCALAB) Stock Analysis & Case Study
Is IPCALAB a good buy? The data-driven verdict.
IPCA Laboratories (IPCALAB) trades at ₹1,597,on the numbers it worth a closer look, a Downstox Snapshot Score of 55/100.
On the numbers, IPCA Laboratories (IPCALAB) worth a closer look, a Downstox Snapshot Score of 55/100, weighing premium at 33.7× earnings, ROE of 16.0%, a 66% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
IPCALAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is IPCALAB overvalued? IPCALAB P/E vs its sector
IPCALAB's P/E of 33.7× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.25% dividend yield is below the peer median of 1.65%.
IPCALAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of IPCALAB history (17%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| IPCALAB 2027 | ₹1,207 | ₹1,798 | ₹2,681 | +13% |
| IPCALAB 2028 | ₹1,180 | ₹2,039 | ₹3,573 | +29% |
| IPCALAB 2029 | ₹1,177 | ₹2,316 | ₹4,583 | +46% |
| IPCALAB 2030 | ₹1,206 | ₹2,648 | ₹5,759 | +67% |
| IPCALAB 2031 | ₹1,243 | ₹3,002 | ₹7,220 | +89% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability IPCALAB goes up, or doubles?
The bull case for IPCALAB
- A healthy 16.0% return on equity.
- A 10,000-path probability model puts a 66% chance the price is higher in a year, with a median target of ₹1,798 (+13%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,583.
The bear case & risks
- At 33.7× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,177.
IPCALAB volatility & expected range, how bumpy is the ride?
Over the last 2.0 years IPCALAB compounded at 17%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹1,207–₹2,681, the honest backbone behind any single price target.
IPCALAB price forecast, the full 60-month probability fan
IPCALAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds IPCALAB hits common targets within the simulated horizon?
Full multi-horizon detail on the IPCALAB price target & forecast page.
IPCALAB Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. IPCALAB scores 4/9,mixed financial health.
IPCALAB MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy IPCALAB with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 29.6% | 3.4× |
| ZerodhaCHEAPEST | 29.6% | 3.4× |
| DhanCHEAPEST | 29.6% | 3.4× |
Compare every broker on the IPCALAB MTF page.
IPCALAB vs peers,sector comparison
About IPCA Laboratories: sector, index & market-cap context
IPCA Laboratories (IPCALAB) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹40,568 Cr. See more Nifty 100 stocks.
How the IPCALAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of IPCA Laboratories's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
IPCALAB analysis, FAQs
Is IPCA Laboratories (IPCALAB) a good buy?
On the numbers, IPCA Laboratories (IPCALAB) worth a closer look, a Downstox Snapshot Score of 55/100, weighing premium at 33.7× earnings, ROE of 16.0%, a 66% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is IPCALAB overvalued or undervalued?
IPCALAB trades at 33.7× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the IPCALAB share price target for 2031?
IPCALAB's probability-weighted 2031 median target is ₹3,002, with an 80% range of ₹1,243–₹7,220 (10,000-path Monte-Carlo).
What is the probability IPCALAB doubles in 5 years?
The modelled probability of IPCALAB reaching ₹3,172 (2×) within 5 years is 47%.
What is the bull case for IPCALAB?
A healthy 16.0% return on equity. A 10,000-path probability model puts a 66% chance the price is higher in a year, with a median target of ₹1,798 (+13%).
What are the risks in IPCALAB?
At 33.7× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.